Argos Therapeutics CSO Dr. Charles Nicolette to Join Panel Discussion on Challenges in Clinical Trial Development at the Society of Gene & Cell Therapy Annual Meeting

        Print
| Source: Argos Therapeutics, Inc.

DURHAM, N.C., May 19, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that company chief scientific officer and vice president of research and development Charles A. Nicolette, Ph.D., will participate in a panel discussion highlighting key issues in late stage development in gene and cell therapy. The discussion, entitled "Things you wish you'd known early on your way to late stage development," will take place on Friday, May 23, 2014, during the 17th Annual Meeting of the American Society of Gene & Cell Therapy at the Marriott Wardman Park Hotel in Washington, DC.

In his presentation, Dr. Nicolette will review the development of AGS-003, Argos' fully personalized immunotherapy, including an update on progress in the pivotal ADAPT phase 3 clinical trial for AGS-003 in the treatment of metastatic renal cell carcinoma.

Program: Panel discussion: "Things you wish you'd known early on your way to late stage development" 
Presentation by Dr. Nicolette: "Taking AGS-003, an RNA-loaded dendritic cell-based immunotherapy, from bench to Phase 3: looking back at the minefield"
Date: Friday, May 23, 2014
Time: 10:30AM – 12:30PM EST
Location: 2660 Woodley Road, NW, Washington, DC

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The company is also developing AGS-004, a personalized immunotherapy for the treatment of HIV, and expects to report data from a Phase 2b trial in mid-2014. For more information about Argos Therapeutics, visit www.argostherapeutics.com.

Media:
Jen Ringler
Berry & Company Public Relations

(212) 253-8881

Investors:
Angeli Kolhatkar
Burns McClellan

(212) 213-0006